Protagonist Therapeutics (NASDAQ: PTGX) reported Q2 EPS of ($0.55), $0.03 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $5.55 million versus the consensus estimate of $7.51 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.